Emergent BioSolutions (EBS) Long-Term Deferred Tax (2016 - 2020)
Historic Long-Term Deferred Tax for Emergent BioSolutions (EBS) over the last 12 years, with Q1 2020 value amounting to $17.6 million.
- Emergent BioSolutions' Long-Term Deferred Tax changed N/A to $17.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was $17.6 million, marking a year-over-year change of. This contributed to the annual value of $13.4 million for FY2019, which is 0.0% changed from last year.
- According to the latest figures from Q1 2020, Emergent BioSolutions' Long-Term Deferred Tax is $17.6 million.
- In the past 5 years, Emergent BioSolutions' Long-Term Deferred Tax ranged from a high of $18.2 million in Q2 2016 and a low of $2.8 million during Q4 2017
- In the last 5 years, Emergent BioSolutions' Long-Term Deferred Tax had a median value of $12.0 million in 2016 and averaged $10.5 million.
- As far as peak fluctuations go, Emergent BioSolutions' Long-Term Deferred Tax crashed by 7239.45% in 2017, and later soared by 37857.14% in 2018.
- Over the past 5 years, Emergent BioSolutions' Long-Term Deferred Tax (Quarter) stood at $6.1 million in 2016, then plummeted by 54.07% to $2.8 million in 2017, then surged by 378.57% to $13.4 million in 2018, then changed by 0.0% to $13.4 million in 2019, then skyrocketed by 31.34% to $17.6 million in 2020.
- Its Long-Term Deferred Tax stands at $17.6 million for Q1 2020, versus $13.4 million for Q4 2019 and $13.4 million for Q4 2018.